CCA
TVTX icon

Catalyst Capital Advisors’s Travere Therapeutics TVTX Stock Holding History

Catalyst Capital Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-45
Closed -$1K – 633
2015
Q4 		$1K Hold
45
– – ﹤0.01% 533
2015
Q3 		$7K Buy
+45
New +$1.33K ﹤0.01% 497

Other funds holding TVTX

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Catalyst Capital Advisors's TVTX Position: Q2 2014 in Review

Catalyst Capital Advisors sold out of Travere Therapeutics (TVTX) in Q2 2014, closing a stake of 84,500 shares — an estimated $1.8M sold.

Catalyst Capital Advisors first reported a position in TVTX in Q1 2014 and held it in 1 quarter. The position peaked at $1.8M in Q1 2014. 59 funds tracked by Wall St. Rank hold TVTX as of Q2 2014.

  • Catalyst Capital Advisors reported no remaining Travere Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Catalyst Capital Advisors sold 84,500 Travere Therapeutics shares in Q2 2014, an estimated $1.8M.
  • Catalyst Capital Advisors first reported a position in Travere Therapeutics in Q1 2014 and held it in 1 quarter.
  • Catalyst Capital Advisors's Travere Therapeutics position peaked at $1.8M in Q1 2014.
  • 59 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2014.

Based on Catalyst Capital Advisors's 13F filing for Q2 2014, filed 12 Aug 2014.